Suggested remit: To appraise the clinical and cost effectiveness of abemaciclib within its marketing authorisation for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer.
Status In progress
Process STA 2018
ID number 3857

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
21 May 2021 In progress. In progress
17 February 2021 - 17 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance